As an early investor in Entrada Therapeutics, we are pleased to share that in 2026 Entrada plans to have four clinical-stage programs in Duchenne – for individuals amenable to skipping exon 44, exon 45, exon 50 or exon 51.
- Exon 44: They are on track to report data from the first cohort of the ELEVATE-44-201 trial in Q2 2026. A Phase 1/2 study in the US is planned to start in the first half of 2026.
- Exon 45: They are on track to report data from first cohort of the ELEVATE-45-201 trial in mid-2026.
- Exon 50: Expect to initiate Phase 1/2 trial in UK and EU by the end of 2026.
- Exon 51: Expect to submit global regulatory applications in 2026.
Link to Press Release: https://ir.entradatx.com/news-releases/news-release-details/entrada-therapeutics-highlights-progress-across-its-portfolio
The post Entrada continues to advance multiple Duchenne exon-skipping programs appeared first on CureDuchenne.